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Abstract
To generate memory B cells bearing high-af®nity antibodies, naive B cells ®rst encounter antigen
in the T cell-rich areas of secondary lymphoid organs. There, they are activated by antigen-speci®c
T cells and become germinal center (GC) founder B cells. GC founders enter the GC to become
centroblasts that proliferate and mutate their BCR. Centroblasts differentiate into centrocytes that
undergo selection, which requires both the recognition/capture of antigen on follicular dendritic
cells and the presentation of processed antigen to GC T cells. Because at each stage of
differentiation B cells act as antigen-presenting cells, we analyzed their content of HLA-DR+-rich
compartments (MIIC), as well as their expression of HLA-DM, which catalyzes peptide loading of
class II molecules, and HLA-DO, which interacts with HLA-DM and focuses MHC class II peptide
loading on antigens internalized by the BCR. Naive and memory B cells concentrate HLA-DR, -DM
and -DO into compartments dispersed under the cell surface, which are identi®ed by their
expression of lysosome-associated membrane protein (Lamp)-1 as late endosomes/lysosomes. GC
founders and GC B cells express larger Lamp-1+DR+ compartments that are concentrated in the
juxta-nuclear region. These compartments express lower levels of HLA-DM and virtually no HLA-
DO. Upon induction of a GC founder phenotype through the prolonged (days) co-ligation of BCR
and CD40, the naive B cell's peripheral DR+DM+Lamp-1+ compartments aggregate in a polar fashion
close to the nucleus. Furthermore, HLA-DO expression virtually disappears, whereas low levels of
HLA-DM remain co-localized with HLA-DR. Anti-k/l antibodies, used as surrogate antigens, are
promptly (minutes) endocytosed in naive, memory and GC B cells. Then, naive and memory B cells
target the surrogate antigen to their peripheral HLA-DO+ MIIC, while GC B cells target it to their
HLA-DO± MIIC aggregates. Taken together, our results show that human GC B cells differ from
naive and memory B cells by their aggregated MIIC that lack HLA-DO.
Introduction
The production of high-af®nity antibodies is dependent on
memory B cells, whose generation requires a complex set of
events that mostly occur within germinal centers (GC) (1±3).
Upon capture of the antigen through the BCR and interaction
with Th cells, IgD+CD38lo naive B cells (4) give rise to
CD38+IgD+ GC founder B cells (5). Within GC, these cells
differentiate into centroblasts that proliferate and introduce
somatic mutations within their variable region genes.
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Centroblasts then differentiate into centrocytes that are
selected based on their ability to (i) recognize and capture
through their BCR antigen presented as immune complexes
on follicular dendritic cells (FDC) (6), and (ii) process and
present the antigen-derived peptides through MHC class II
complexes to memory GC T cells that, in return, drive the
B cells to switch isotype (7±9) and differentiate into either
memory or plasma cells (8). When a B cell encounters its
speci®c antigen, the BCR is endocytosed and transported into
the endosomal/lysosomal compartments. There the antigen is
degraded into peptides that form complexes with MHC class II
molecules. These MHC class II compartments have been
extensively studied in B cell lines, either of human origin
(4,10±13) or mouse origin (14±18). Studies with B cell lines
also suggested that MHC II-rich compartments (MIIC) are
altered following BCR engagement (15,16,19±21). These
studies were extended to murine splenocytes expressing
transgenic anti-egg lysozyme BCR (22). However, no infor-
mation is available concerning the expression of these
compartments in distinct B cell subsets.
MHC class II peptide loading is controlled by the invariant
chain (Ii/CD74), and the non-classical MHC molecules HLA-
DM and -DO (23±25). Newly synthesized MHC class II
molecules associate in the endoplasmic reticulum with
Ii/CD74, which facilitates MHC class II transport from the
endoplasmic reticulum into MIIC. In this location, Ii/CD74 is
cleaved by proteases that leave the class II-associated
invariant chain peptide (CLIP) in the peptide-binding groove
(26). Release of CLIP, necessary for peptide binding to MHC
class II molecules, requires the action of HLA-DM (27±31).
HLA-DM molecules are expressed in all antigen-presenting
cells including B cells, dendritic cells and epithelial cells (32).
In mutant cell lines or mice lacking functional H2-M, CLIP
remains associated to class II, which results in a qualitatively
altered CD4+ T cell repertoire (33). In B cells, a considerable
number of HLA-DM molecules are not present as free
heterodimers, but are associated with HLA-DO in heterote-
trameric complexes (19,30). HLA-DO is a non-polymorphic
heterodimer closely related to classical MHC class II
molecules. It is commonly accepted that HLA-DO molecules
are restricted to B cells and to some cortical thymic epithelial
cells (34), and play a role in regulating the activity of HLA-DM
by focusing antigen presentation to antigens internalized
through the BCR (33). HLA-DO was described as a negative
regulator of HLA-DM activity (35,36) because its over-expres-
sion in transfected cell lines increases the amount of CLIP-
containing MHC class II molecules at the cell surface. HLA-DO
was also shown to restrict DM activity essentially at mildly
acidic pH and to in¯uence the repertoire of MHC class II-
associated peptides (37,38).
The expression of MHC class II molecules is relevant to
the different functional consequences of antigen presenta-
tion by the different types of B cells, as naive B cells
induce tolerance (39), memory B cells induce immunity
and GC B cells probe themselves for survival. To this end,
we have analyzed the expression of the different
components of the MHC class II antigen presentation
machinery, HLA-DM, -DO, CD74 and CLIP, in naive B cells,
GC founder B cells, and GC B cells (centroblasts and
centrocytes) and memory B cells from tonsils and blood.
Naive and memory B cells concentrate HLA-DR, -DM and -
DO into compartments dispersed under the cell surface. In
contrast, GC B cells aggregate in their juxta-nuclear region
their MIIC that express virtually no HLA-DO. Accordingly,
co-ligation of BCR and CD40 in naive B cells promptly
down-regulates HLA-DO expression and induces re-organ-
ization of their MIIC. Finally, antigens in the form of anti-l/k
are rapidly internalized in the various B cell subsets, and
reach both the peripheral and deep MIIC.
Methods
Antibodies
Cell separation and staining was performed using the follow-
ing antibodies: puri®ed mouse anti-CD2, -CD3, -CD4, -CD16,
-CD14, -CD56, -CerCLIP (clone CerCLIP), -DM (clone
Map.DM1), -lysosome-associated membrane protein
(Lamp)-1 and -mouse IgG1 (all purchased from PharMingen,
San Diego, CA); mouse anti-HLA-DR (clone L243) and
biotinylated anti-HLA-DR (Becton Dickinson, San Jose, CA);
pure and FITC-conjugated mouse anti-CD38, -CD27, FITC±
goat anti-IgA, FITC±goat anti-IgG, mouse IgG2a and mouse
IgG2b (Caltag, Burlingame, CA); anti-CD39 and -HLA-DR
(clone L243) (Immunotech, Marseilles, France); FITC- and
phycoerythrin (PE)-conjugated goat anti-IgD (Southern
Biotechnology Associates, Birmingham, AL); mouse anti-
CD74 (Biosource, Camarillo, CA); mouse anti-DO (clone
DOB.L1) (gift from Dr G. Moldenhauer, DKFZ, Germany);
FITC-conjugated rabbit anti-human-l/k (Dako, Carpinteria,
CA); secondary antibodies Texas Red- and Cy5-conjugated
donkey anti-mouse IgG (Jackson ImmunoResearch, West
Grove, PA); and streptavidin±Cy5 (Caltag).
Fluorescent-labeled cells were analyzed on a ¯ow
cytometer (FACSCalibur; Becton Dickinson) or mounted in
¯uoromount mounting medium (Southern Biotechnology
Associates) for confocal microscopy. All micrographs
were recorded using a confocal microscopy system
equipped with three Ar488, Kr568 and HeNe633 lasers
(TCS-SP; Leica, Mannheim, Germany) as well as spectro-
photometers.
B cell puri®cation
Unseparated B cells were puri®ed from mononuclear cells,
isolated after Ficoll-Hypaque gradient centrifugation (Cellgro),
using B cell-enrichment kits (Miltenyi, Auburn, CA) and
magnetic columns (MACS). This procedure routinely provided
>95% pure B cells. For naive B cells, tonsil mononuclear cells
were enriched by the standard Ficoll-Hypaque gradient
method and subjected to E-rosetting with sheep red blood
cells to eliminate T cells. Non-rosetting cells were labeled with
anti-CD2, -CD3, -CD4, -CD16, -CD14 and -CD56 to remove
T cells and monocytes, anti-CD38 mAb to remove GC B cells,
and anti-CD27mAb to remove memory B cells. Cells were
subsequently incubated with goat anti-mouse IgG magnetic
microbeads (Miltenyi) and labeled cells were eliminated using
a magnetic column, leading to 80±95% pure naive B cells after
two runs. For immuno¯uorescence of GC B cells, cells were
puri®ed and negatively selected as mentioned above, but
using mouse anti-CD39 and FITC-conjugated goat anti-IgD to
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label naive B cells. Cells were then incubated with goat anti-
mouse IgG and anti-FITC±magnetic microbeads to eliminate
labeled cells with the MACS system, leading to 85±95% pure
GC B cells after two runs. For Western blotting, cells were
sorted by FACS (FACS Vantage; Becton Dickinson) after
labeling with FITC-conjugated anti-CD38 and PE-conjugated
anti-IgD, leading to >95% purity. For immunohistochemistry on
isolated tonsil plasma cells, plasma cells were sorted by FACS
(FACS Vantage) after labeling of enriched B cells with
anti-CD38.
Flow cytometry
To detect cell-surface markers, enriched B cells were stained
with non-conjugated mAb, anti-HLA-DR, -DO, -DM, -CD74
and -CerCLIP, revealed by a Cy5-conjugated donkey anti-
mouse IgG. Cells were then incubated with mouse serum
10%, and stained with PE-conjugated goat anti-IgD and FITC-
conjugated mouse anti-CD38. For intracellular detection, cells
were ®rst labeled with anti-IgD±PE (Southern Biotechnology
Associates) and anti-CD38±FITC, then incubated with goat
Fab fragments anti-mouse IgG and permeabilized using a
permeabilization kit (PharMingen) prior to indirect staining with
anti-HLA-DR, -DO and -DM revealed by Cy5-conjugated
donkey anti-mouse IgG. Controls were performed using non-
conjugated isotype controls.
Immunohistochemistry
Tonsil sections were ®xed for 15 min in acetone at 4°C and
washed twice with PBS. After quenching with PBS/BSA 0.5%
and ®sh gelatin 0.1%, staining was performed by incubating
®rst one of the following indirect mouse mAb, anti-HLA-DR
-DM, -DO, anti-CD74 or anti-CerCLIP, revealed by Cy5±
donkey anti-mouse antibodies in PBS/BSA 0.5%/saponin
0.1%. The directly coupled FITC±anti-IgD antibody was then
added following a quenching step with 10% mouse serum in
PBS/BSA 0.5%. Preparations were mounted with ¯uoromount
and micrographs were captured using the objective 320, HC
PL APO.
For cell suspensions, cells were allowed to adhere for 1 h on
slides previously coated with 0.1 mg/ml poly-L-lysine (Sigma,
St Louis, MO) for 1 h at room temperature and ®xed with 4%
paraformaldehyde. After quenching with PBS/glycine (50 mM),
cells were permeabilized with Triton X-100 (0.1%) for 10 min.
They were subsequently washed with PBS/saponin (0.2%) and
quenched with PBS/BSA/®sh gelatin before staining with one
indirect antibody alone. These antibodies (anti-HLA-DR, -DO
and -DM) were revealed by a Texas Red±anti-mouse IgG.
Cells were then incubated with mouse serum 10% and stained
using FITC-labeled antibody (anti-IgD, -IgA, -IgG and -l/k).
For triple staining, streptavidin±Cy5 (Caltag) was used to
detect biotinylated anti-HLA-DR. Preparations were mounted
with ¯uoromount and micrographs were recorded using the
objectives 363 or 3100 PL APO with zoom 2.
Quantitative Western blot analysis
Cells (106) were lysed in 50 ml lysis buffer (20 mM Tris, pH 7.5,
5 mM MgCl2 and 1% Triton X-100) containing protease
inhibitors (PMSF, pepstatin, chymostatin and leupeptin) for 1 h
at 4°C. After removal of nuclei and cell debris, samples were
supplemented with Laemmli sample buffer, boiled and loaded
on a 12% SDS gel. After transfer onto an Immobilon PVDF
membrane (Millipore, Bedford, MA), the membrane was
blocked with Blocking reagent (Roche, Nutley, NJ) and
stained with the respective primary antibodies (1B5 recogniz-
ing DRa, DM.K8 recognizing DMb and DOB.L1 recognizing
DOb) followed by incubation with horseradish peroxidase-
conjugated, isotype-speci®c secondary antibodies (Southern
Biotechnology Associates). Staining was visualized with
Super-Signal Dura West (Pierce, Rockford, IL). Quantitative
analysis was performed on a LumiImager F1 (Roche) using
LumiAnalyst software (Roche).
B cell cultures
Naive B cells were cultured in RPMI 1640 (Gibco, Grand
Island, NY) with 10% FCS (Sigma) and antibiotics at 106/ml in
24-well plates, in the presence of 105/ml irradiated L cells,
either transfected with the human Fc receptor CD32 only or
double-transfected with CD40 ligand (CD40L) and CD32.
Mouse anti-human l/k antibodies were added at 50 ng/ml to
cross-link the BCR. Cells were harvested at day 6 for
intracellular examination of HLA-DR, -DM and -DO expression
by confocal immuno¯uorescence microscopy.
BCR internalization
Naive and memory B cells from blood and tonsil GC B cells
were puri®ed by negative selection. After staining at 4°C with
anti-k and anti-l antibodies, these were cross-linked by a
Texas Red-conjugated secondary antibody. Cells were
warmed up at 37°C by addition of warm medium, and after
30 min cells were washed with cold PBS and placed to adhere
on a poly-L-lysine-coated slide at 4°C. Staining with FITC±anti-
HLA-DR was performed after permeabilization with PBS/Triton
X-100, and a quenching step with PBS/BSA/saponin and
mouse serum 10%.
Results
Distinct MIIC in distinct human B cell subsets
As different human B cell subsets display remarkably different
functional properties, we questioned whether they would differ
in their antigen-presenting machinery. As described earlier
(4,40), puri®ed tonsil B cells can be separated into four
different B cell subsets using FITC-labeled anti-CD38 and PE-
labeled anti-IgD antibodies (Fig. 1A). Naive (IgD+CD38±) and
GC (IgD±CD38+) B cells were sorted and deposited on slides
for confocal ¯uorescence microscopy. As shown in Fig. 1(B, a
and b), most intracellular HLA-DR molecules of naive B cells
reside within peripheral compartments dispersed beneath the
cell surface. These compartments co-express the lysosome-
associated membrane protein, Lamp-1 (Fig. 1B-a). HLA-DM
(Fig. 1C, a, b, g and h) and -DO (Fig. 1C, d and e) molecules
are also found within intracellular compartments, and dual
staining indicates that these molecules are co-localized within
the HLA-DR-rich compartments (Fig. 1C, a, d and g).
Puri®ed GC B cells display a strikingly different organization
of their MIIC, as none of these cells have the peripheral MIIC of
naive B cells. Rather, GC B cells display aggregates of many
small HLA-DR+ compartments located next to the nucleus,
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likely within the peri-centriolar region of the cells (Fig. 1B, e,
and C, i and l). These compartments co-express Lamp-1
(Fig. 1B, d), show reduced levels of HLA-DM (Fig. 1C, g and h)
and virtually no HLA-DO (Fig. 1C, j and k). These compart-
ments are likely equivalent to the MIIC identi®ed earlier in B cell
lines (4,10,14,41).
Thus all naive B cells express a collection of small peripheral
MIIC, while GC B cells express larger MIIC aggregates in the
juxta-nuclear region of the cells.
HLA-DM and -DO are down-regulated in GC B cells
The alterations of HLA-DM and -DO expression observed in
GC B cells were further analyzed by immunohistochemical
staining of tonsil sections. As opposed to anti-IgD staining that
easily distinguishes follicular mantles from GC (Fig. 2A, a, c
and e), anti-HLA-DR distinguishes T cell-rich areas from B cell-
rich areas, but does not discriminate, within follicles, GC from
mantle zones (Fig. 2A, b). In contrast, anti-HLA-DM reveals an
Fig. 1. Distinct MHC class II-rich compartments in naive and GC B cells. (A) Flow cytometry analysis of tonsillar B cell subsets. B cells were
puri®ed by negative selection using magnetic beads, and labeled with PE-labeled anti-IgD and FITC-labeled anti-CD38: IgD+CD38± naive
B cells (R1); IgD+CD38+ pre-GC B cells (R2); IgD±CD38+ GC B cells (R3); IgD±CD38± memory B cells (R4). (B) Dispersed peripheral MIIC in
naive B cells and deep aggregated MIIC in GC B cells. Sorted naive (upper panel) and GC (lower panel) B cells were deposited on slides,
and analyzed by confocal microscopy using Texas Red-labeled anti-HLA-DR and FITC-labeled anti-Lamp. Left panel (a and d): merge;
middle panel (b and e): anti-HLA-DR; right panel (c and f): anti-Lamp-1. Confocal microscopy, objective 363, zoom 2. (C) HLA-DM/DO are
co-localized with HLA-DR in naive B cells and down-regulated in GC B cells. B cell subsets were sorted by FACS to yield naive B cells (a±f)
and GC B cells (g±l) for confocal immuno¯uorescence analysis of HLA-DR, -DM and -DO expression. The micrographs recorded with identical
settings reveal that intracellular HLA-DR is co-localized with HLA-DM and -DO in naive B cells (yellow and orange dots in a±d). In GC B cells,
HLA-DO expression is markedly down-regulated (j±k), whereas HLA-DM is only slightly reduced (g±h). Confocal microscopy, objective 3100,
zoom 2.
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intense labeling of naive B cell-rich follicular mantles, con-
trasting with the GC areas that stain faintly (Fig. 2A, d). A
monoclonal anti-HLA-DO antibody also revealed intense
staining of follicular mantles, while GC were negative
(Fig. 2A, f). Thus, consistent with previous information (42),
naive B cells express DM/DO, but the present data indicate
that GC B cells express DM/DO at much lower levels.
In situ staining with anti-HLA-DM does not permit us to
appreciate: (i) the stage at which B cells loose DM/DO
expression, i.e. GC founders or centroblasts, or (ii) the
expression of DM/DO in memory B cells. To this end, the
expression pattern of DM/DO was further analyzed by ¯ow
cytometry on suspensions of puri®ed B cells stained with FITC-
labeled anti-CD38 and PE-labeled anti-IgD. A third color, Cy5,
can be used to study expression of MHC class II molecules.
This analysis ®rst showed that none of the subsets expresses
DM/DO on their surface, unlike previous reports on human B
cell lines (38). As shown in Fig. 2(B), IgD+CD38lo naive B cells
express intracellular DM/DO. However, CD38hiIgD± GC B cells
express only very low levels of DM/DO, a result consistent with
the in situ data reported above. GC founder B cells, which
express both IgD and high levels of CD38, also display low
levels of DM/DO, indicating a prompt down-regulation of these
molecules following cognate activation of naive B cells.
Quantitative Western blots analysis (25) of HLA-DR, -DM and
-DO on puri®ed B cell subsets (Fig. 2C) further shows that the
HLA-DM content is slightly reduced in GC B cells compared to
naive B cells, while HLA-DO is drastically reduced in GC
B cells. The DO/DM ratio (calculated based on an absolute
amount of puri®ed HLA-DR used as standard) in naive B cells
is 2.13 (mean of two independent experiments), while it is 0.30
in GC B cells.
Taken together, these data demonstrate that upon entry into
a GC reaction, B cells promptly down-regulate their expres-
sion of HLA-DO.
Dual ligation of CD40 and BCR in naive B cells down-
regulates HLA-DO and -DM
At least two signals are required for the formation of GC:
antigen encounter and CD40 ligation (1,2). To assess their
eventual role in the down-regulation of HLA-DM/DO within GC
B cells, naive B cells were cultured over L cells expressing
CD40L and CD32 (Ig Fc receptor) in the presence of anti-BCR
antibodies, as surrogates for T cells and antigen respectively
(43). Under these conditions, naive B cells differentiate into
large blasts (Fig. 3d and i) and proliferate [(33) and not
shown]. These B cell blasts display large aggregates of
intracellular HLA-DR+ compartments comparable to those of
GC B cells. These compartments contain intermediate levels
of HLA-DM (Fig. 3g and h). The in vitro generated GC-like
B cells barely express HLA-DO, while they retain high levels of
HLA-DR (Fig. 3d, f, g and i). Conversely, naive B cells cultured
for 6 days on irradiated untransfected L cells preserve their
naive phenotype, i.e. they remain small, express sIgD and
maintain their HLA-DO molecules co-localized with HLA-DR in
intracellular compartments (Fig. 3a and c). Single triggering of
naive B cells cultured for 6 days with L cells expressing CD32
with anti-BCR led to signi®cant cell death in the absence of
CD40 ligation (not shown); yet the remaining viable cells still
express HLA-DO. In contrast, CD40L signaling alone results in
partial down-regulation of HLA-DO (data not shown).
These results indicate that in vitro signals that trigger a
partial GC phenotype on naive B cells induce a reorganization
of their MIIC and a down-regulation of HLA-DO, both typical of
GC B cells.
Memory B cells, but not plasma cells, re-express HLA-DO
and -DM
Once selected, high-af®nity GC B cells develop into memory
B cells or plasma cells. Flow cytometry analysis of puri®ed
tonsillar B cells identi®es memory B cells as CD38loIgD± cells
(gate R4 in Fig. 1A), and demonstrates that they express both
HLA-DM and -DO at levels comparable to those observed in
naive B cells (Fig. 2B, last row). Blood B cells are composed
mainly of naive IgD+ and memory IgA+ or IgG+ cells. Confocal
analysis of puri®ed blood B cells indicates that HLA-DO and -
DR are co-expressed within intracellular compartments in
memory IgA+ B cells, as found above with naive B cells
(Fig. 4A, a and e). Thus, GC B cells re-express HLA-DM/DO
when they differentiate into memory B cells. Furthermore,
these data indicate that naive and memory B cells of both
blood and tonsils display a comparable HLA-DM/DO pattern.
While tonsillar plasma cells express high levels of surface
HLA-DR (44), these cells do not express intracellular HLA-DR+
compartments. Dual staining with either anti-HLA-DO or -DM
further shows that they do not express these non-classical
MHC molecules (Fig. 4B, a and d). Thus, upon differentiation
into the plasma cell pathway, GC B cells further down-regulate
their HLA-DM/DO, while they re-express these molecules
while differentiating into the memory cell pathway. The lack of
HLA-DM/DO expression in plasma cells is not unexpected, as
these cells are not considered to act as antigen-presenting
cells despite the presence of surface HLA-DR.
Memory and GC B cells express less CLIP within their HLA-
DR molecules than naive B cells
The release of CLIP, the Ii/CD74-derived peptide, is necessary
for exogenous peptide binding to the MHC class II molecules
(12,45). Thus, we analyzed the expression of Ii/CD74 and the
levels of CLIP peptides associated to HLA-DR molecules in
the different B cell subsets. On tonsil sections, Ii/CD74
expression appears higher in GC B cells than in naive B cells
from follicular mantles, while CerCLIP labeling is higher in
follicular mantles than in GC (data not shown). Flow cytometry
shows that Ii/CD74 is most expressed on GC founder B cells,
and at comparable intensity on naive and memory B cells
(Fig. 5, second column). The surface expression of CerCLIP is
highest on naive B cells, decreases on GC founder B cells,
and is lowest on GC and memory B cells (Fig. 5, third column).
Thus, a large proportion of naive B cell HLA-DR surface
molecules are engaged with CLIP peptide, leaving few
molecules for self- and non-self-peptide presentation. In
contrast, a higher proportion of memory B cell HLA-DR
surface molecules is devoid of CLIP and thus presumably
engaged with other peptides.
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All human GC B cell subsets capture and target antigen±
BCR complexes into HLA-DR compartments
As we have shown that different human B cell subsets express
unique MIIC, we next analyzed whether they target antigen
differently. The BCR is the main vehicle for B cells to capture
and internalize antigen (46). Resting B cells express high
levels of BCR on their cell surface, whereas GC B cells have
lower amounts of BCR on their cell surface [(1) and data not
shown]. Puri®ed GC B cells from tonsils as well as naive and
memory B cells from blood were incubated with anti-BCR, and
then cross-linked with a secondary antibody to trigger clus-
tering and internalization of the surrogate antigen. Naive,
memory and GC B cells incubated at 4°C bear the cross-
linked BCR molecules on their cell surface (Fig. 6a and d).
After 30 min incubation at 37°C, naive and memory B cells
internalize the surrogate antigen in peripheral MIIC (Fig. 6b),
while GC B cells internalize it into their juxta-nuclear MIIC
(Fig. 6d).
Thus, despite their apparent structural differences, the MIIC
within normal human B cell subsets represent the targets of
endocytosed BCR-captured antigens.
Discussion
The present study on normal human mature B cell subsets
isolated from blood and tonsils, a major secondary lymphoid
organ, reveals several important new features related to
antigen presentation: (i) the presence in naive/memory
B cells of multiple small peripheral MIIC distinct from the
large juxta-nuclear aggregates of GC B cells, (ii) the lack of
HLA-DO in GC B cells, (iii) the down-regulation of HLA-DO and
Fig. 2. Down-regulation of HLA-DM and -DO in GC B cells. (A) Confocal immuno¯uorescence microscopy. Acetone-®xed tonsil tissue sections
labeled with anti-IgD (a, c and e) and with either anti-HLA-DR (n = 4), -DM (n = 3) or -DO (n = 5) antibodies (b, d and f). HLA-DR molecules
are expressed at similar levels in the follicular mantle that contains naive B cells and in GC containing GC B cells. HLA-DM and -DO
expression is reduced in GC B cells compared to the IgD+ naive B cells of the follicular mantle zone. Confocal microscopy, objective 320. (B)
Down-regulation of intracellular HLA-DM and -DO in GC B cells. Puri®ed B cells were labeled with PE-labeled anti-IgD, FITC-labeled anti-
CD38: IgD+CD38± naive B cells (R1); IgD+CD38+ pre-GC B cells (R2); IgD±CD38+ GC B cells (R3); IgD±CD38± memory B cells (R4) and
labeled with a third marker, HLA-DM/DO (thick line) and isotype control (shaded graph). Note the lack of HLA-DM/DO on the surface of all
tonsil B cell subsets, and the down-regulation of intracellular HLA-DM/DO in pre-GC B cells (R2) and GC B cells (R3). (C) Western blot
analysis of HLA-DR, -DM and -DO in sorted naive and GC B cell populations.
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Fig. 3. Dual ligation of CD40 and BCR in naive B cells down-
regulates HLA-DO. Puri®ed naive B cells were cultured for 6 days
with irradiated L cells either transfected with CD32 alone, to maintain
the naive phenotype, or double-transfected with CD40L and CD32
supplemented with anti-l/k to generate a partial GC phenotype.
Confocal micrographs with identical settings show co-localized
intracellular HLA-DR and -DO molecules in naive B cells (a). The
intracellular HLA-DO labeling is lost once naive B cells are
converted into large B cell blasts after BCR engagement and CD40
ligation in culture (d and e), while HLA-DM expression is maintained
at a low level (g and h). Confocal microscopy, objective 3100,
zoom 2.
Fig. 4. Memory B cells re-express HLA-DO in peripheral MIIC. (A)
HLA-DO and -DR are co-localized in puri®ed blood naive and
memory B cells. Puri®ed blood B cells were labeled with anti-HLA-
DO (red) (e), anti-DR (blue) (d), and anti-IgA and -IgG (b). In
memory IgA+/IgG+ B cells, HLA-DO and -DR are co-localized in
intracellular compartments as in naive B cells (c). Confocal
microscopy, objective 363, zoom 2. (B) Lack of HLA-DM/DO in
tonsillar plasma cells. Tonsil tissue specimens (a±c) were labeled
with FITC-labeled anti-IgA (a and b) and FITC-labeled anti-IgD (c),
and puri®ed tonsil plasma cells were labeled with FITC±anti-k/l (d),
and counter-stained with Texas Red-coupled anti-HLA-DO antibody
(a±d). The subepithelial IgA+ plasma B cells (a and b), the IgD+
plasma B cells (C) and the puri®ed IgD+ B cells (d) are devoid of
HLA-DO. Confocal microscopy, objective 310 (a), 340 (b), 320 (c),
3100, zoom 2 (d).
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the merging of MIIC in naive B cells provided with GC-
triggering signals, i.e. co-ligation of CD40 and BCR, and (iv)
the internalization and targeting of the antigen±BCR com-
plexes by naive and GC B cells into their MIIC.
We demonstrate that human B cells remodel their MHC
class II compartments when they enter into a GC reaction.
Naive and memory B cells concentrate HLA-DR molecules into
numerous peripheral compartments located immediately
under the cell surface, which also contain HLA-DM and -DO.
As they also co-express Lamp-1, they qualify as late
endosomes/lysosomes. This is at variance with studies on
established murine B cell lines that share some characteristics
of normal resting B cells (14,21). There, electron microscopy
shows that, under a resting state, the murine B cell lymphoma
line expresses MHC class II molecules in compartments
distinct from Lamp-1+ compartments. Two possibilities may
explain the discrepancy between these studies: (i) the lack of
sensitivity, in our study, of the confocal analysis which would
not discriminate the two independent compartments and (ii)
the use, in the other study, of proliferating B cell lines that may
not be comparable to normal non-proliferating naive B cells.
Herein we further show that upon induction of a GC founder
phenotype, through co-ligation of BCR and CD40, these
DR+DM+Lamp-1+ compartments aggregate deeper inside the
cells. This ®nding extends to normal human B cells the
remodeling, aggregation and fusion of the Lamp-1+ compart-
ments described, in response to BCR ligation, in murine B cell
lines (15,16,19±21). The studies with the B cell lines concluded
that these newly generated compartments are more acidic,
favoring the activity of HLA-DM and inhibiting the activity of
HLA-DO (16). Our results on normal B cells yield a different
conclusion, i.e. the disappearance of HLA-DO. Yet, the
functional consequences are equivalent as the remaining
HLA-DM is now able to fully exert its activity of peptide loading
onto MHC II molecules in GC B cells.
The tonsillar GC founder cells (IgD+CD38+) express, on their
cell surface, higher levels of HLA-DR and Ii/CD74 than naive
and memory B cells, indicating synthesis of new MHC II
molecules that are sent to the cell surface before integrating
intracellular compartments. Studies on B cell lines, which
display a constitutively activated CD40 signal transduction
pathway (47), indicated that the loading of antigen through the
BCR occurs onto newly synthesized MHC II molecules (48).
Therefore, when naive B cells encounter their speci®c antigens
and receive a T cell signal (most likely CD40L), new class II
molecules are synthesized, possibly to provide the novel pool
needed by the centroblasts for their selection. Our previous
studies on murine splenic B cells showed that BCR ligands are
uniquely presented by newly synthesized MHC class II
molecules (49), and that the linked roles of antigen inter-
nalization and B cell activation of the BCR leads to potent
Ii/CD74-dependent antigen presentation (49). In summary, the
prolonged co-ligation of naive B cells, BCR and CD40 brings
numerous features of GC B cells including morphology (size
and merging of MIIC), phenotype with the exception of CD10
(43) and functions such as intense proliferation as well as a
basic level of somatic mutations (50).
Our study further demonstrates that GC B cell MIIC, at
variance with cell lines, do not express HLA-DO. The lack of
HLA-DO apparently loosens the stringency of antigen pre-
sentation by GC B cells. This is likely to be needed in GC
centroblasts, as fast probing of BCR quality is needed in
response to their considerable proliferation that permits
introduction of multiple somatic mutations to create variants
with a higher af®nity for the eliciting antigen. There, the cells
which cycle every 6±7 min (1) need to be ef®ciently tested for
Fig. 5. Low levels of CLIP on GC and memory B cells. Puri®ed tonsil
B cells were triple labeled with PE-labeled anti-IgD, FITC-labeled
anti-CD38 and Cy5-labeled anti-HLA-DR, CD74 or CerCLIP as the
third marker for ¯ow cytometry analysis of their surface expression.
CerCLIP labeling is reduced on the surface of pre-GC, GC and
memory B cells.
Fig. 6. Naive and GC B cells internalize BCR±anti-BCR complexes
within MIIC. Puri®ed naive (upper panel) and GC (lower panel)
B cells were incubated at 4°C with anti-k and anti-l antibodies, and
then with Texas Red-conjugated secondary antibody as surrogate
BCR ligand. Cells were warmed up at 37°C by addition of warm
medium, and after 0 and 30 min cells were washed with cold PBS,
allowed to adhere on poly-L-lysine-coated slides at 4°C, and
analyzed by confocal immuno¯uorescence microscopy for HLA-DR
(green) and internalized surrogate BCR ligands (red). Confocal
microscopy, objective 363, zoom 2.
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reactivity with the antigen that is presented by the FDC
network. Indeed, our preliminary data suggest that GC B cells
endocytose the antigen into MIIC within 5 min, while naive
B cells do not show internalization after 5 min, but after 30 min.
Thus faster antigen endocytosis and a less strict peptide
selection, as implied by the lack of HLA-DO, may contribute to
a faster selection of desired high-af®nity GC mutants. The
overall low stringency of antigen processing in GC B cells
when compared to naive and memory cells is possible
because: (i) GC B cells have already been antigen-selected
outside the GC and (ii) GC are a `hard nut to crack', penetrated
by very few exogenous antigens and thus avoiding selection
of undesired speci®cities that may arise as a consequence of
somatic mutation (51).
A signi®cant observation of this study is the higher density of
CLIP on the surface of naive B cells when compared to GC and
memory B cells. This indicates that naive B cells have a limited
presentation of MHC class II±foreign peptide complexes.
Naive cells may thus be compared to HLA-DO transfectants,
which are de®cient in antigen presentation (35,36). Upon
differentiation into a GC founder, following antigen and
speci®c T cell encounter, remodeling of the MIIC and loss of
HLA-DO accelerate peptide-loading activity leading to the
decrease of CLIP on the cell surface. These ®ndings therefore
extend to normal B cells earlier observations made with
Epstein±Barr virus-transformed B cell lines and HLA-DM
transfectants where free HLA-DM molecules catalyze CLIP
removal from MHC class II molecules (33).
Once selected, GC B cells differentiate into memory B cells
or plasma cells. The memory B cells re-express HLA-DO as
well as MIIC dispersed in peripheral locations, suggesting the
intriguing possibility that HLA-DO may actually be involved in
the formation of these peripheral compartments. Memory
B cells, at variance with naive B cells, have low CLIP on their
surface. This likely re¯ects the presence of other self or
exogenous peptides derived from antigens processed during
GC reactions. Plasma cells, the antibody-producing cells,
loose their system of antigen-processing capacity (lack of
MIIC, and HLA-DO and -DM), even though they still express
surface HLA-DR at high density (44), the function of which
remains to be elucidated.
Down-regulation of HLA-DM and -DO in human GC B cells
has been recently described by two different groups (52,53).
These studies, however, did not address the redistribution of
MIIC in puri®ed GC B cell suspensions nor did they analyze
the signals that contribute to the down-regulation of these
molecules upon activation of naive B cells. Roucard et al. have
reported the down-modulation of HLA-DM and -DO in vitro
upon culture of cell lines and blood naive B cells with phorbol
myristate acetate or soluble anti-IgM (54). We activated naive
B cells with cross-linked anti-BCR and CD40L, the combin-
ation of signals that best reproduces the GC phenotype in vitro.
These combined signals led to the down-regulation of HLA-
DM and -DO, while isolated anti-BCR triggering led to B cell
death.
In conclusion, human B cell subsets appear to have distinct
mechanisms of antigen processing. The naive and memory
B cells display small super®cial MIIC that contain HLA-DM and
-DO as described earlier with B cell lines. In contrast, GC
founder B cells reorganize MIIC into large clusters that do not
contain HLA-DO.
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CD40L CD40 ligand
CLIP class II-associated invariant chain peptide
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